Ocular Therapeutix (NSDQ:OCUL) touted data today from a patient experience study of its Dextenza post-surgical pain relief implant. The study was published in Patient Preference and Adherence. The Bedford, Mass.-based company’s hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. After the […]
Clinical Trials
Abiomed touts reduced acute kidney risk in Impella-supported PCI study
Abiomed (NSDQ:ABMD) today released data from a study which utilized its Impella 2.5 heart pump for hemodynamic support during high-risk percutaneous coronary interventions, touting reduced risk of acute kidney injury in patients with preexisting kidney disease and low ejection fraction. Data from the study were recently published in the journal Circulation Research, the Danvers, Mass.-based […]
Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplasty
Pacira Pharmaceuticals (NSDQ:PCRX) said today the Phase IV study of its Exparel bupivacaine liposome injection in patients undergoing total knee arthroplasty met its co-primary endpoints for postsurgical pain and opioid reduction. The anesthetic achieved statistical significance for secondary endpoints including time to 1st opioid use and the percentage of patients who did not require opioids […]
Masimo touts study of SpHb monitoring tech
Masimo (NSDQ:MASI) today released results from a study which compared the company’s noninvasive SpHb measurement to conventional laboratory HbL measurements for patients undergoing liver transplantation, touting equivalence between the 2 methods. Researchers in the study reported that Masimo’s SpHb monitoring had “clinically acceptable accuracy of hemoglobin measurement [compared] with a standard laboratory device when used during […]
Cartiva touts 5-year synthetic cartilage study data
Cartiva touted 5-year data for its synthetic cartilage implant in patients with arthritis at the base of the big toe. The data, which included results from 27 patients, were published in Foot and Ankle International. The study found that patients experienced a 91% mean reduction in pain after 5 years and a 128% mean improvement in sporting […]
Aethlon touts Hemopurifier feasibility study results
Aethlon Medical (NSDQ:AEMD) said today that it finished an FDA-approved feasibility study for its Hemopurifier device in health-compromised patients. Previously, the device was used under the FDA’s emergency-use authorization in patients infected with Hepatitis C, HIV and the Ebola virus. Aethlon’s Hemopurifier device is a single-use, disposable cartridge designed to target and filter out viruses or tumor-secreted […]
BioTime expands OpRegen dry-AMD trial with U.S. sites
BioTime Inc. (NYSE:BTX) said today that it expanded its OpRegen Phase I/IIa trial into the U.S. with 2 new trial sites. The company’s study is evaluating its OpRegen cell therapy in patients with advanced dry form age-related macular degeneration. The 2 U.S.-based trial sites will include ophthalmologists Dr. David Boyer from the Retina-Vitreous Associates Medical Group […]
7 medtech stores we missed this week: March 10, 2017
The FDA and Health Canada cleared a couple medical devices while other companies touted their device studies. Here are 7 medtech stories we missed this week but were still worth mentioning. 1. FDA clears Medela’s neonatal enteral feeding device Medela has received 510(k) clearance from the FDA to market its ENFit Low Dose Tip eternal […]
InVivo enrolls another patient in Inspire trial
InVivo Therapeutics (NSDQ:NVIV) said today that it enrolled a new patient in the Inspire study of its neuro-spinal scaffold. Principal investigator Dr. Patrick Hsieh performed the implantation earlier this week, 82 hours after the patient’s spinal cord injury happened. “The implantation of the neuro-spinal scaffold went smoothly and the patient is recovering well,” Hsieh said in […]
Medtronic launches DCB clinical trial for below-the-knee peripheral artery disease
Medtronic (NYSE:MDT) said today that it launched a clinical trial to evaluate the use of its In.Pact paclitaxel-coated percutaneous transluminal angioplasty balloon catheter in patients with below-the-knee peripheral arterial disease. The company treated its 1st patient in the In.Pact BTK study, performing the procedure on a patient with critical limb ischemia. Get the full story at […]
PolyPid touts early data for BonyPid-1000 antibiotic-eluting bone substitute
PolyPid touted interim data today from the 1st group of patients to reach the 6-month follow-up period in the clinical trial of its BonyPid-1000 doxycycline-eluting synthetic bone substitute. The Israel-based company’s clinical trial enrolled 64 patients with open tibia fractures. In this type of fracture, the bone is severely damaged and exposed, leaving it vulnerable […]